DexCom (DXCM) Tops Q2 EPS by 44c, Revenues Beat; Offers FY20 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
DexCom (DXCM) PT Raised to $540 at Cowen
July 24, 2020 8:07 AM EDTCowen analyst Doug Schenkel raised the price target on DexCom (NASDAQ: DXCM) to $540.00 (from $450.00) while maintaining an Outperform rating.
The analyst commented, "UnitedHealthcare recently announced the launch of its Level2 program for Type 2 diabetes management. All participants are required to wear a DXCM... More
